Information Provided By:
Fly News Breaks for June 10, 2015
PCRX
Jun 10, 2015 | 08:17 EDT
Goldman said recent data points on Exparel support its view that risk/reward is favorable. The firm received positive physician feedback that Exparel demand remains strong despite some investor concerns. Goldman expects sentiment to improve with a potential reacceleration in Exparel demand and Phase 3 data in oral surgery by year end. The firm continues to view Pacira as an attractive takeout target and reiterates its Buy rating and $104 price target.
News For PCRX From the Last 2 Days
There are no results for your query PCRX